Want to see JP:4583 full AI Analyst Report?
Chiome Bioscience Inc. (4583) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cba-1535, Cba-1535+Pembrolizumab | Solid Tumors, Refractory Cancer | Phase I | Recruiting | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | Apr 07, 2025 | ― |
| Cba-1205 Part 1, Cba-1205 Part 2, Cba-1205 Part 3, Cba-1205 Part 4, Cba-1205 Part 5 | Solid Tumors, Malignant Melanoma, Hepatocellular Carcinoma (Hcc), Pediatric Cancer | Phase I | Recruiting | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | Sep 30, 2024 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cba-1535, Cba-1535+Pembrolizumab | Phase I | Solid Tumors, Refractory Cancer | Recruiting | A Phase I, First in Human Study of CBA-1535, T Cell Engager(5T4/CD3/5T4) in Patients With Advanced Solid Tumors. | Apr 07, 2025 | ― |
| Cba-1205 Part 1, Cba-1205 Part 2, Cba-1205 Part 3, Cba-1205 Part 4, Cba-1205 Part 5 | Phase I | Solid Tumors, Malignant Melanoma, Hepatocellular Carcinoma (Hcc), Pediatric Cancer | Recruiting | A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer | Sep 30, 2024 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Chiome Bioscience Inc. (JP:4583) have in its pipeline
Chiome Bioscience Inc. JP:4583 is currently developing the following drugs: Cba-1535, Cba-1535+Pembrolizumab, Cba-1205 Part 1, Cba-1205 Part 2, Cba-1205 Part 3, Cba-1205 Part 4, Cba-1205 Part 5. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
